Fig 1.
Patient enrollment, follow-up, and serological study analysis flowchart.
Table 1.
Demographic and clinical profiles of study population (Tunisia 2020).
Fig 2.
Temporal Evolution of Antibody Responses (IgM and IgG) Against Nucleocapsid (N) and Spike (S) Proteins in Individuals Over Time: Mean and 95% Confidence Intervals.
Table 2.
Serum antibody levels (IgG and IgM) in male and female subjects over time post- infection with the first SARS-CoV-2 variant.
Table 3.
Serum antibody response (IgG and IgM) in different age groups (≤40 and >40 years) post- infection with the first SARS-CoV-2 variant.
Table 4.
Serum antibody response (IgG and IgM) in symptomatic and asymptomatic individuals following infection with the first SARS-CoV-2 variant.